A phase I/IIa trial of tolerogen for the treatment of myasthenia gravis

Trial Profile

A phase I/IIa trial of tolerogen for the treatment of myasthenia gravis

Planning
Phase of Trial: Phase I/II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Acetylcholine receptor peptide fragments (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Sep 2016 Planned initiation date changed from 1 Jan 2017 to 1 Jan 2018, according to Toleranzia media release.
    • 12 Aug 2016 According to a Toleranzia media release, this trial is expected to initiate in 2017.
    • 18 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top